Published online before print April 19, 2007, doi: 10.1161/01.RES.0000267744.92677.7f
© 2007 American Heart Association, Inc.
Cellular Biology |
The Troponin C G159D Mutation Blunts Myofilament Desensitization Induced by Troponin I Ser23/24 Phosphorylation
From the Department of Physiology and Biophysics and Center for Cardiovascular Research, College of Medicine, University of Illinois, Chicago.
Correspondence to Pieter P. de Tombe, Department of Physiology and Biophysics, University of Illinois, 835 S Wolcott Ave (M/C 901), Chicago, IL 60612. E-mail PdeTombe{at}uic.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Striated muscle contraction is regulated by the binding of Ca2+ to the N-terminal regulatory lobe of the cardiac troponin C (cTnC) subunit in the troponin complex. In the heart, ß-adrenergic stimulation induces protein kinase A phosphorylation of cardiac troponin I (cTnI) at Ser23/24 to alter the interaction of cTnI with cTnC in the troponin complex and is critical to the regulation of cardiac contractility. We investigated the effect of the dilated cardiomyopathy linked cTnC Gly159 to Asp (cTnC-G159D) mutation on the development of Ca2+-dependent tension and ATPase rate in whole troponin-exchanged skinned rat trabeculae. Even though this mutation is located in the C-terminal lobe of cTnC, the G159D mutation was demonstrated to depress ATPase activation and filament sliding in vitro. The effects of this mutation within the cardiac myofilament are unknown. Our results demonstrate that the cTnC-G159D mutation by itself does not alter the myofilament response to Ca2+ in the cardiac muscle lattice. However, in the presence of cTnI phosphorylated at Ser23/24, which reduced Ca2+ sensitivity and enhanced cross-bridge cycling in controls, cTnC-G159D specifically blunted the phosphorylation induced decrease in Ca2+-sensitive tension development without altering cross-bridge cycling. Measurements in purified troponin confirmed that this cTnC-G159D blunting of myofilament desensitization results from altered Ca2+-binding to cTnC. Our results provide novel evidence that modification of the cTnC-cTnI interaction has distinct effects on troponin Ca2+-binding and cross-bridge kinetics to suggest a novel role for thin filament mutations in the modulation of myofilament function through ß-adrenergic signaling as well as the development of cardiomyopathy.
Key Words: skinned muscle • rat • human • tension cost • cross-bridge cycling • cardiomyopathy
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Although familial cardiomyopathies are genetically associated with mutations of a large number of amino acid residues in most of the sarcomeric proteins, only 2 mutations in the Ca2+ receptor responsible for activating cardiac sarcomeric contraction, cardiac troponin C (cTnC), have been recently demonstrated as linked to cardiomyopathy. In the current study, we report the functional effects of the dilated cardiomyopathy linked cTnC Gly159 to Asp (cTnC-G159D) mutation identified by Mogensen et al.1 The site of this mutation is of particular interest as it is located within the C-terminal lobe of cTnC generally considered to be structural, rather than regulatory.
cTnC is a bilobed metal-binding protein that functions as the Ca2+-sensing subunit of the troponin (Tn) complex also containing cardiac troponin I (cTnI), the inhibitory protein, and cardiac troponin T (cTnT), the tropomyosin (Tm)-binding protein, to regulate the Tm inhibition of the actin–myosin interaction. Both the cTnC N- and C-lobes contain metal-binding sites, but it is the binding of Ca2+ to a single site located in the N-regulatory lobe that regulates contraction, whereas divalent cation binding to the C-lobe has been considered structural, reviewed in.2 In diastole and the absence of Ca2+, cTnC exists in a "closed" conformation and the cTnI C-terminal region binds actin tightly, contributing to inhibition of the actin–myosin interaction. In systole, Ca2+ binding to the cTnC N-regulatory lobe induces an "open" conformation that exposes a cTnI binding site removing cTnI inhibition.
The binding of Ca2+ to the cTnC N-regulatory lobe in cardiac myofilaments is modulated by ß-adrenergic receptor stimulation via activation of protein kinase A (PKA) and the subsequent phosphorylation of cTnI at Ser23/24 through mechanisms unique to cardiac muscle. The phosphorylation of cTnI Ser23/24 in the N-terminal extension of the cardiac isoform has been well established to diminish the myofilament Ca2+ sensitivity of activation, tension, and ATPase rate by reducing the affinity of the cTnC N-regulatory site for Ca2+.3 Interestingly, unlike the binding of Ca2+ to the cTnC regulatory site, cTnI phosphorylation at Ser23/24 also induces structural alterations within the cTnC C-lobe, including the interaction of cTnI with cTnC residue Gly159.4 In view of the G159D location within the cTnC C-lobe and the effect of cTnI phosphorylation on cTnC residue Gly159, we sought to determine whether this mutation alters myofilament function in the presence of cTnI Ser23/24 phosphorylation.
We report here the results of experiments in which we investigated the effects of the cTnC-G159D mutation on Ca2+ regulation of myofilament tension and cross-bridge cycling rate in Tn-exchanged skinned rat trabeculae, both in the absence and presence of cTnI Ser23/24 phosphorylation. Our results demonstrate that the mutation by itself does not alter myofilament function. However, in the presence of cTnI phosphorylation the mutation virtually eliminates the characteristic cTnI Ser23/24 phosphorylation–induced myofilament desensitization in the absence of an effect on cross-bridge cycling. These data provide novel insights into the linkage of the TnC-G159D mutation to cardiomyopathy and the role of the cTnI-cTnC C-lobe interaction in ß-adrenergic modulation of myofilament function.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
cDNA Constructs
The human cardiac cTnC-G159D mutation and human cardiac TnI Ser23/24 pseudo-phosphorylation (cTnI-DD) cDNA were constructed by site-directed mutagenesis (Quick Change II kit; Stratagene). The cTnC-G159D construction was performed by mutagenesis of the human cTnC cDNA codon encoding Gly159 to Asp.1 The construction of the cTnI-DD charge mutation to mimic Ser23/24 phosphorylation was performed by mutagenesis of the human cTnI cDNA codons encoding Ser23/24 to Asp. The single Cys mutant human cardiac wild type and TnC-G159D were constructed as previously described.5
Tn Expression, Purification, and Complex Reconstitution
The recombinant human wild-type cTnC, cTnC-G159D, and human cTnIs were expressed and purified as previously described.5 The expression and purification of the recombinant human cTnT containing an N-terminal myc tag was performed as previously described with slight modification of the purification protocol.6 Tn complex was reconstituted by sequential dialysis to remove urea and decrease salt of an equimolar amount of Tn components and purified using Resource-Q chromatography as previously described.5 Fractions containing pure Tn were dialyzed against exchange buffer (in mol/L): KCl 200, MgCl2 5, EGTA 5, dithiothreitol (DTT) 1, MOPS 20 (pH 6.5); aliquots were stored at –80°C until use.
Exchange of Recombinant Cardiac Tn Into Skinned Rat Trabeculae
All animals were handled in accordance with the guidelines of the Animal Care and Use Committee at the University of Illinois, Chicago. Free-running, unbranched right ventricular trabeculae from male Lewis brown Norway–F1 rats (Harlan Laboratories; 
14 weeks of age) were dissected, treated with Triton X-100 to extract membranes (skinned), and attached to aluminum T-clips as previously described.7 Endogenous Tn from trabeculae was exchanged for exogenous Tn by overnight incubation at 4°C in 13 µmol/L recombinant cardiac Tn containing (in mol/L) KCl 200, MgCl2 5, EGTA 5, DTT 1, MOPS 20 (pH 6.5) as previously described.6
Simultaneous Measurement of Isometric Tension and ATPase Activity
The simultaneous measurement of steady-state isometric tension and myofibrillar ATPase as a function of free [Ca2+] was conducted as previously described.7 Sarcomere length was set to 2.2 µm by laser diffraction and trabeculae activated over a range of free [Ca2+] to measure steady-state isometric tension and ATPase activity. Only muscles that maintained greater then 80% maximal tension were included for analysis. Following the mechanical experiment, each trabeculae was briefly dried and stored frozen for biochemical analysis.
Quantification of Tn Exchange by Western Blot
Recombinant cTnT in the present experiments included an N-terminal myc tag to allow for quantification of the amount of Tn exchange by Western blotting techniques.6 Previously we have demonstrated that the presence of this myc tag does not affect myofilament function.8
Tn Complex Ca2+-Binding Affinity
Ca2+ binding was measured by fluorescence emission intensity of 2-(4'-iodoacetamido)anilino-naphthalene-6-sulfonic acid (IAANS) attached to Cys35 in a single Cys mutant cTnC (C84S) of the Tn complex as described previously.5 The solutions contained (in mol/L): NaCl 100, MgCl2 5, EGTA 1, DTT 1, MOPS 20 (pH 7.0); titrations with Ca2+ were performed at 25°C, and free [Ca2+] was calculated with the WEBMAXC program.9
Data Processing and Statistical Analysis
Tension–Ca2+ relationships were fit to a modified Hill equation7; tension cost was determined by linear fit to the tension–ATPase data. Statistical analyses were performed either as multiple linear regression, 1-way or 2-way ANOVA as appropriate using the R statistical analyses packages. P<0.05 was considered statistically significant; data are presented mean±SEM.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Skinned Trabeculae Exchange With Recombinant Exogenous Tn
We used the whole Tn-exchange technique as a means to investigate the functional effect of the cTnC-G159D mutation on sarcomere dynamics in the cardiac myofilament lattice. We generated and purified recombinant wild-type (WT-Tn) and mutated human Tn consisting of the cTnC-G159D mutation (G159D-Tn), Ser23/24 Asp pseudo-phosphorylated cTnI to mimic phosphorylation at these residues (WT-Tn-DD), or cTnC-G159D in the presence of the Ser23/24 Asp pseudo-phosphorylated cTnI (G159D-Tn-DD). Analysis of the various purified Tn complex preparations by SDS-PAGE revealed 3 protein bands without detectable evidence of protein degradation (Figure 1A). Recombinant cTnT migrates slower than the endogenous rat cTnT allowing the electrophoretic separation of exogenous from endogenous cTnT for subsequent Tn exchange quantification of each trabeculae independently by Western blot using a cTnT-specific monoclonal antibody CT3 (Figure 1B). On average, trabeculae included in the analyses contained 68.4±2.7% recombinant human cTnT. Furthermore, the presence of the cTnC-G159D, the cTnI-DD, or the combination of these did not significantly affect the extent of Tn exchange.
|
cTnC-G159D Alone Does Not Alter Myofilament Function
As illustrated in Figure 2A, exchange of human Tn containing the cTnC-G159D mutation into skinned rat cardiac trabeculae did not significantly alter myofilament Ca2+ sensitivity, cooperativity, or maximum tension development compared with trabeculae exchanged with human wild-type Tn. Furthermore, as shown in Figure 2B, there was a small, but insignificant, increase in ATP-hydrolysis rate at all levels of tension, indicating that this mutation alone does not affect the cycling kinetics of strongly bound, tension-developing cross-bridges. There was also a lack of the mutant cTnC to affect tension cost (Figure 2B, inset), a parameter reflecting the rate of cross-bridge detachment.7 The average parameters of the Hill fit to the tension data and tension cost obtained in each individual muscle preparation support this notion (Table 1).
|
|
cTnC-G159D Blunts the Impact of cTnI Ser23/24 Pseudo-Phosphorylation on Myofilament Function
In light of the cTnC G159D’s location within the Tn complex and its altered environmental change on cTnI Ser23/24 phosphorylation,4 we hypothesized that the cTnC-G159D mutation may have different effects on cardiac contractile function following ß-adrenergic stimulation. To investigate this hypothesis we used a recombinant cTnI with Ser residues 23 and 24 mutated to negatively charged Asp (cTnI-DD) to mimic ß-adrenergic–stimulated, PKA-mediated phosphorylation of cTnI at these residues. The cTnI-DD mutation has previously been demonstrated to mimic the effects of cTnI PKA phosphorylation at Ser23/24 both structurally4,10 and functionally in cardiac trabeculae.11,12 Figure 3A demonstrates the well-known13 impact of cTnI Ser23/24 phosphorylation to desensitize the myofilament to Ca2+ observed as a significant right shift of the tension–Ca2+ relationship. Maximum myofilament tension–generating capacity was also slightly reduced, albeit not significantly (Figure 3A, inset). Moreover, myofilament ATP hydrolysis rate and the tension cost parameter were significantly increased (Figure 3B), indicating that Ser23/24 pseudo-phosphorylation of cTnI induced an acceleration of cross-bridge cycling kinetics. We next investigated the impact of cTnC-G159D on myofilament function in the presence of the cTnI-DD. As is shown in Figure 4A, the cTnC-G159D mutation almost completely abolished the characteristic decrease in myofilament Ca2+ sensitivity that normally accompanies cTnI Ser23/24 phosphorylation. In contrast, maximum tension generating capacity remained similar to that observed in the presence of the WT-Tn-DD (Figure 4A, inset). Furthermore, exchange of the G159D-Tn-DD did not alter the rate of ATP hydrolysis or tension cost compared to the WT-Tn-DD, both of which were significantly increased from that observed in WT-Tn exchanged trabeculae (Figure 4B). The average fit parameters are summarized in Table 1.
|
|
cTnC-G159D Blunts the Impact of cTnI Ser23/24 Pseudo-Phosphorylation on Tn Ca2+-Binding Affinity
It is established that the decreased myofilament Ca2+ sensitivity following Ser23/24 phosphorylation of cTnI is associated with a decrease in Ca2+-binding affinity to the Tn complex.3 The absence of the characteristic cTnI phosphorylation–induced myofilament Ca2+ desensitization in the presence of cTnC-G159D (Figure 4A) could, therefore, be attributable to a direct effect of this mutation to inhibit the modulation of Tn Ca2+-binding affinity by cTnI phosphorylation. Consistent with the lack of an affect on the tension–Ca2+ relationship in skinned cardiac trabeculae (Figure 2A), the presence of cTnC-G159D alone did not affect Tn Ca2+-binding affinity (Figure 5). Furthermore, cTnI-DD induced a decrease in Tn Ca2+-binding affinity that was prevented in the presence of cTnC-G159D, consistent with the results obtained in Tn exchanged skinned cardiac trabeculae (Figures 3A and 4
A). The average fit parameters of these data are summarized in Table 2.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The results presented here represent the first investigation to test the effects of a cTnC cardiomyopathy-linked mutation in the cardiac myofilament lattice and provide new insights not only into the molecular pathology but also in the molecular mechanisms that underlie the modulation of myofilament function through ß-adrenergic signaling. A previous report demonstrated that the cTnC-G159D mutation induced a decrease in ATPase activity of reconstituted myofilaments as well as filament sliding velocity in an in vitro motility assay.14 Another study demonstrated the exchange of the cTnC-G159D into fast skeletal fibers did not affect the development of steady-state tension but reduced the rate of tension development on rapid Ca2+ activation.15 Similar to the findings in skeletal muscle, we demonstrate here that the cTnC mutation exhibits no effect on the Ca2+-regulated steady-state tension or ATP-hydrolysis rate when exchanged into cardiac myofilaments (Figure 2). In addition to this finding, our data further demonstrate that cardiac filaments regulated by cTnC-G159D lack the characteristic Ca2+ desensitization that normally results from the presence of cTnI phosphorylated by PKA (Figure 4). This inability of sarcomeres regulated by cTnC-G159D to respond to cTnI PKA-mediated phosphorylation is likely to alter myocardial functional responses, especially the ß-adrenergic–induced reduction in cardiac cycle length. Studies16 using a transgenic mouse model have demonstrated that cTnI Ser23/24 phosphorylation, acting in conjunction with the phosphorylation of membrane proteins involved in Ca2+ homeostasis, is essential to the increased cardiac relaxation required to maintain adequate diastolic ventricular filling during the shortened contractile cycle induced by ß-adrenergic stimulation. Thus our data predict an impairment of myocardial relaxation during elevated ß-adrenergic activity, for example, as occurs during exercise, and this phenomenon may trigger maladaptive cardiac remodeling similar to the dilated cardiomyopathy that is observed in individuals who express the cTnC-G159D mutation.1
The lusitropic effects of cTnI phosphorylation at Ser23/24 appear to result from 2 separate functional mechanisms (Figure 6B): (1) a decrease in the Ca2+-binding affinity of the cTnC N-terminal regulatory domain to decrease the Ca2+-sensitive activation of the thin filament17,18 and (2) an increase in cross-bridge cycling rate.17,19 Increased cross-bridge cycling attributed to cTnI PKA phosphorylation at Ser23/24 has been observed in some,17,20 but not all,7,10 studies using a variety of techniques such as velocity of shortening,21 rate of tension development, and frequency of minimum stiffness.19 The inconsistency of these findings may result from PKA treatment–mediated phosphorylation of other cardiac contractile proteins, notably myosin binding protein C or titin, to mask the effect of cTnI Ser23/24 phosphorylation on cross-bridge cycling. Here we overcame this confounding factor by exchanging endogenous Tn in skinned cardiac trabeculae with recombinant human Tn containing cTnI Ser23/24 mutated to the negatively charged Asp residue (cTnI-DD). The exchange of cTnI-DD allows for investigation of the sole effects of cTnI Ser23/24 phosphorylation in the absence of other potentially confounding PKA-mediated cytoskeletal protein phosphorylation. The mutation cTnI Ser23/24 residues to Asp functions both structurally4,10 and functionally,10,11 similar to PKA-mediated phosphorylation of cTnI in cardiac muscle. Indeed, in the present study, we observed both the characteristic decrease in Ca2+ sensitivity of steady-state tension (Figure 3) and a decrease in binding affinity of Ca2+ to Tn containing the recombinant cTnI-DD (Figure 5). Furthermore, we demonstrate an increase in tension cost (a measurement of cross-bridge detachment rate) in the presence of cTnI pseudo-phosphorylated at Ser23/24 (Figure 3) that, unlike Ca2+-desensitzation, was not affected by the presence or absence of the cTnC-G159D mutation (Figure 4). This increase in cross-bridge detachment rate, as measured by tension cost, is supported by our previous findings demonstrating that cTnI PKA phosphorylation increases the rate of force relaxation and minimum dynamic stiffness,19 as well as work from other investigators including an increase in the velocity of shortening following PKA treatment.21 The separate functional effects of cTnI PKA phosphorylation are also consistent with our recent observation that exchange of Tn containing slow skeletal TnI induced an alteration in myofilament Ca2+ sensitivity without affecting activation/relaxation dynamics.22 Together these findings support the notion that the impact of cTnI Ser23/24 phosphorylation on myofilament Ca2+ sensitivity and cross-bridge cycling rate function independently through separate and distinct mechanisms (Figure 6B).
|
The molecular mechanism of how the cTnC-G159D mutation blunts the decrease in myofilament Ca2+ sensitivity on cTnI Ser23/24 phosphorylation remains to be identified. Our results indicate that cTnC-G159D blunts the cTnI Ser23/24 N-terminal phosphorylation–induced decrease of myofilament Ca2+ sensitivity by altering the binding affinity of Ca2+ to the cTnC N-terminal regulatory lobe (Figure 5 and Table 2), suggesting a direct effect of cTnC C-lobe residue 159 on Ca2+ binding to the cTnC N-regulatory lobe in a phospho-specific manner. Consistent with this finding, biochemical studies investigating the function of various TnI fragments support the notion of a role for the TnI N terminus as responsible for regulating Ca2+ sensitivity, whereas the C-terminal region may function to regulate cross-bridge cycling kinetics.23 In the absence of Ser23/24 phosphorylation, the cTnI N-terminal extension binds to the cTnC N-regulatory lobe to stabilize the open conformation.4,24–26 After cTnI Ser23/24 phosphorylation, incorporation of the negatively charged phosphates repels the cTnI N-terminal extension, causing it to bend and rotate away from the main axis27,28 (Figure 6A). This conformational change in the cTnI N-terminal extension is believed to weaken its interaction with the cTnC N-lobe,4,24–26 causing a shift of the regulatory domain open/closed conformational distribution toward the closed conformation to decrease Ca2+-binding affinity. The phosphorylation of cTnI Ser23/24 also induces a shift in the NMR chemical signal that results from the interaction of the cTnI N terminus with the cTnC C-lobe, including the cTnI interaction with cTnC residue Gly159.4,10 The cTnC-G159D mutation has previously been demonstrated to increase the binding affinity of cTnC to cTnI.1 This increase in binding affinity may strengthen the interaction between the cTnI N terminus and the cTnC C-lobe to inhibit the Ser23/24 phosphorylation weakening of the cTnI N-terminal extension/cTnC N-lobe interaction and prevent the shift in the open/closed conformation of the cTnC regulatory lobe responsible for decreased Ca2+-binding affinity (Figure 6A). The detailed mechanisms how the cTnC-G159D mutation alters cardiac contraction and the binding of Ca2+ to cTnC solely in the presence of the cTnI Ser23/24 phosphorylation is of great interest and deserves further investigation.
The cTnC Gly159 residue resides in a highly conserved region of the C-lobe that directly and tightly interacts with the cTnI N terminus29 and is generally not considered to be involved in myofilament regulation. We report here that the cTnC-G159D mutation inhibits cTnI PKA-mediated phosphorylation induced Ca2+ desensitization (Figures 4 and 5). This finding extends our earlier studies demonstrating the importance of the cTnC C-lobe in myofilament regulation. One indication of the importance of this cTnC-cTnI region in the regulation of the myofilament in response to Ca2+ is found in the binding of the Ca2+-sensitizing agent EMD 57003 to the cTnC C-lobe. We have previously demonstrated that cTnI phosphorylation at Ser43/45 (a region that also interacts with the TnC C-lobe) is sufficient to modify the impact of EMD 57033 on myofilament Ca2+ sensitivity.30 Furthermore, we have reported that the cTnI N-terminal region surrounding Ala66, a region that strongly interacts with the cTnC C-lobe, is a significant locus of signaling in the activation of the thin filament by strongly bound cross-bridges.31 Together with these previous findings, our current results provide further evidence indicating a unique role for the cTnC C-lobe interaction with the cTnI N terminus in myofilament contractile regulation.
A significant finding from our experiments is the linkage of increased myofilament Ca2+ sensitivity with dilated cardiomyopathy. Mutations in sarcomeric proteins associated with dilated cardiomyopathy typically demonstrate decreased myofilament Ca2+ sensitivity, yet the effect of the cTnC-G159D to inhibit cTnI phosphorylation–induced myofilament Ca2+ desensitization functions to effectively increase Ca2+ sensitivity. Alterations of cTnI phosphorylation levels are suggested to be important in the development of human cardiomyopathy. Increased myofilament Ca2+ sensitivity has been reported by some investigators in end-stage heart failure and is most likely associated with the reduced basal PKA-mediated phosphorylation of cTnI32 resulting from decreased ß-adrenergic signaling through cAMP.32,33 Although it has been difficult to ascertain whether the increased myofilament Ca2+ sensitivity observed in end-stage human heart failure is related to the development of this condition, our data indicate that the altered myofilament response to Ca2+ may be an important factor in the transition of the failing heart to a dilated phenotype.
|
Acknowledgments |
|---|
We thank Minae Kobayashi for discussions contributing to the development of these experiments and Stacey Schwartz for technical assistance. The CT3 monoclonal antibody developed by J.J.-C. Lin was obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the National Institute of Child Health and Human Development and maintained by the Department of Biological Sciences at the University of Iowa (Iowa City).
Sources of Funding
This work was supported by NIH grant T32 07692. B.J.B is supported by a NIH postdoctoral fellowship (F32 HL082109). T.K (R01 HL082923), R.J.S, and P.P.d.T. are supported by NIH grants R01 HL 64035, HL 75494, and P01 HL 62426 projects 1 and 4.
Disclosures
None.
|
Footnotes |
|---|
Original received January 12, 2007; revision received March 27, 2007; accepted April 10, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Mogensen J, Murphy RT, Shaw T, Bahl A, Redwood C, Watkins H, Burke M, Elliott PM, McKenna WJ. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2004; 44: 2033–2040.
2. Kobayashi T, Solaro RJ. Calcium, thin filaments, and the integrative biology of cardiac contractility. Annu Rev Physiol. 2005; 67: 39–67.[CrossRef][Medline] [Order article via Infotrieve]
3. Holroyde MJ, Robertson SP, Johnson JD, Solaro RJ, Potter JD. The calcium and magnesium binding sites on cardiac troponin and their role in the regulation of myofibrillar adenosine triphosphatase. J Biol Chem. 1980; 255: 11688–11693.
4. Finley N, Abbott MB, Abusamhadneh E, Gaponenko V, Dong W, Gasmi-Seabrook G, Howarth JW, Rance M, Solaro RJ, Cheung HC, Rosevear PR. NMR analysis of cardiac troponin C-troponin I complexes: effects of phosphorylation. FEBS Lett. 1999; 453: 107–112.[CrossRef][Medline] [Order article via Infotrieve]
5. Kobayashi T, Solaro RJ. Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I. J Biol Chem. 2006; 281: 13471–13477.
6. Sumandea MP, Pyle WG, Kobayashi T, de Tombe PP, Solaro RJ. Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J Biol Chem. 2003; 278: 35135–35144.
7. de Tombe PP, Stienen GJ. Protein kinase A does not alter economy of force maintenance in skinned rat cardiac trabeculae. Circ Res. 1995; 76: 734–741.
8. Chandra M, Rundell VL, Tardiff JC, Leinwand LA, De Tombe PP, Solaro RJ. Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T. Am J Physiol Heart Circ Physiol. 2001; 280: H705–H713.
9. Patton C, Thompson S, Epel D. Some precautions in using chelators to buffer metals in biological solutions. Cell Calcium. 2004; 35: 427–431.[CrossRef][Medline] [Order article via Infotrieve]
10. Sakthivel S, Finley NL, Rosevear PR, Lorenz JN, Gulick J, Kim S, VanBuren P, Martin LA, Robbins J. In vivo and in vitro analysis of cardiac troponin I phosphorylation. J Biol Chem. 2005; 280: 703–714.
11. Dohet C, al-Hillawi E, Trayer IP, Ruegg JC. Reconstitution of skinned cardiac fibres with human recombinant cardiac troponin-I mutants and troponin-C. FEBS Lett. 1995; 377: 131–134.[CrossRef][Medline] [Order article via Infotrieve]
12. Takimoto E, Soergel DG, Janssen PM, Stull LB, Kass DA, Murphy AM. Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase A phosphorylation sites. Circ Res. 2004; 94: 496–504.
13. Solaro RJ, Moir AJ, Perry SV. Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature. 1976; 262: 615–617.[CrossRef][Medline] [Order article via Infotrieve]
14. Mirza M, Marston S, Willott R, Ashley C, Mogensen J, McKenna W, Robinson P, Redwood C, Watkins H. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J Biol Chem. 2005; 280: 28498–28506.
15. Preston LC, Lipscomb S, Robinson P, Mogensen J, McKenna WJ, Watkins H, Ashley CC, Redwood CS. Functional effects of the DCM mutant Gly159Asp troponin C in skinned muscle fibres. Pflugers Arch. 2006: 771–776.
16. Wolska BM, Arteaga GM, Pena JR, Nowak G, Phillips RM, Sahai S, de Tombe PP, Martin AF, Kranias EG, Solaro RJ. Expression of slow skeletal troponin I in hearts of phospholamban knockout mice alters the relaxant effect of beta-adrenergic stimulation. Circ Res. 2002; 90: 882–888.
17. Hunlich M, Begin KJ, Gorga JA, Fishbaugher DE, LeWinter MM, VanBuren P. Protein kinase A mediated modulation of acto-myosin kinetics. J Mol Cell Cardiol. 2005; 38: 119–125.[CrossRef][Medline] [Order article via Infotrieve]
18. Wattanapermpool J, Guo X, Solaro RJ. The unique amino-terminal peptide of cardiac troponin I regulates myofibrillar activity only when it is phosphorylated. J Mol Cell Cardiol. 1995; 27: 1383–1391.[CrossRef][Medline] [Order article via Infotrieve]
19. Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, Solaro RJ. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res. 2001; 88: 1059–1065.
20. Strang KT, Sweitzer NK, Greaser ML, Moss RL. Beta-adrenergic receptor stimulation increases unloaded shortening velocity of skinned single ventricular myocytes from rats. Circ Res. 1994; 74: 542–549.
21. Herron TJ, Korte FS, McDonald KS. Power output is increased after phosphorylation of myofibrillar proteins in rat skinned cardiac myocytes. Circ Res. 2001; 89: 1184–1190.
22. de Tombe PP, Belus A, Piroddi N, Scellini B, Walker JS, Martin AF, Tesi C, Poggesi C. Myofilament calcium sensitivity does not affect cross-bridge activation-relaxation kinetics. Am J Physiol Regul Integr Comp Physiol. 2007; 292: R1129–R1136.
23. Van Eyk JE, Thomas LT, Tripet B, Wiesner RJ, Pearlstone JR, Farah CS, Reinach FC, Hodges RS. Distinct regions of troponin I regulate Ca2+-dependent activation and Ca2+ sensitivity of the acto-S1-TM ATPase activity of the thin filament. J Biol Chem. 1997; 272: 10529–10537.
24. Abbott MB, Dong WJ, Dvoretsky A, DaGue B, Caprioli RM, Cheung HC, Rosevear PR. Modulation of cardiac troponin C-cardiac troponin I regulatory interactions by the amino-terminus of cardiac troponin I. Biochemistry. 2001; 40: 5992–6001.[CrossRef][Medline] [Order article via Infotrieve]
25. Gaponenko V, Abusamhadneh E, Abbott MB, Finley N, Gasmi-Seabrook G, Solaro RJ, Rance M, Rosevear PR. Effects of troponin I phosphorylation on conformational exchange in the regulatory domain of cardiac troponin C. J Biol Chem. 1999; 274: 16681–16684.
26. Ward DG, Brewer SM, Gallon CE, Gao Y, Levine BA, Trayer IP. NMR and mutagenesis studies on the phosphorylation region of human cardiac troponin I. Biochemistry. 2004; 43: 5772–5781.[CrossRef][Medline] [Order article via Infotrieve]
27. Dong WJ, Chandra M, Xing J, She M, Solaro RJ, Cheung HC. Phosphorylation-induced distance change in a cardiac muscle troponin I mutant. Biochemistry. 1997; 36: 6754–6761.[CrossRef][Medline] [Order article via Infotrieve]
28. Heller WT, Finley NL, Dong WJ, Timmins P, Cheung HC, Rosevear PR, Trewhella J. Small-angle neutron scattering with contrast variation reveals spatial relationships between the three subunits in the ternary cardiac troponin complex and the effects of troponin I phosphorylation. Biochemistry. 2003; 42: 7790–7800.[CrossRef][Medline] [Order article via Infotrieve]
29. Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature. 2003; 424: 35–41.[CrossRef][Medline] [Order article via Infotrieve]
30. Burkart EM, Arteaga GM, Sumandea MP, Prabhakar R, Wieczorek DF, Solaro RJ. Altered signaling surrounding the C-lobe of cardiac troponin C in myofilaments containing an alpha-tropomyosin mutation linked to familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2003; 35: 1285–1293.[CrossRef][Medline] [Order article via Infotrieve]
31. Engel PL, Kobayashi T, Biesiadecki B, Davis J, Tikunova S, Wu S, Solaro RJ. Identification of a region of troponin I important in signaling cross-bridge-dependent activation of cardiac myofilaments. J Biol Chem. 2007; 282: 183–193.
32. Zakhary DR, Moravec CS, Stewart RW, Bond M. Protein kinase A (PKA)-dependent troponin-I phosphorylation and PKA regulatory subunits are decreased in human dilated cardiomyopathy. Circulation. 1999; 99: 505–510.
33. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111: 2837–2849.
This article has been cited by other articles:
 |
|
 |
|
  J. R. Pinto, M. S. Parvatiyar, M. A. Jones, J. Liang, M. J. Ackerman, and J. D. Potter A Functional and Structural Study of Troponin C Mutations Related to Hypertrophic Cardiomyopathy J. Biol. Chem., July 10, 2009; 284(28): 19090 - 19100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Scruggs, A. C. Hinken, A. Thawornkaiwong, J. Robbins, L. A. Walker, P. P. de Tombe, D. L. Geenen, P. M. Buttrick, and R. J. Solaro Ablation of Ventricular Myosin Regulatory Light Chain Phosphorylation in Mice Causes Cardiac Dysfunction in Situ and Affects Neighboring Myofilament Protein Phosphorylation J. Biol. Chem., February 20, 2009; 284(8): 5097 - 5106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dweck, N. Hus, and J. D. Potter Challenging Current Paradigms Related to Cardiomyopathies: ARE CHANGES IN THE Ca2+ SENSITIVITY OF MYOFILAMENTS CONTAINING CARDIAC TROPONIN C MUTATIONS (G159D AND L29Q) GOOD PREDICTORS OF THE PHENOTYPIC OUTCOMES? J. Biol. Chem., November 28, 2008; 283(48): 33119 - 33128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Morimoto Sarcomeric proteins and inherited cardiomyopathies Cardiovasc Res, March 1, 2008; 77(4): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Davis and S. B. Tikunova Ca2+ exchange with troponin C and cardiac muscle dynamics Cardiovasc Res, March 1, 2008; 77(4): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-J. Dong, J. Xing, Y. Ouyang, J. An, and H. C. Cheung Structural Kinetics of Cardiac Troponin C Mutants Linked to Familial Hypertrophic and Dilated Cardiomyopathy in Troponin Complexes J. Biol. Chem., February 8, 2008; 283(6): 3424 - 3432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Robinson, P. J. Griffiths, H. Watkins, and C. S. Redwood Dilated and Hypertrophic Cardiomyopathy Mutations in Troponin and {alpha}-Tropomyosin Have Opposing Effects on the Calcium Affinity of Cardiac Thin Filaments Circ. Res., December 7, 2007; 101(12): 1266 - 1273. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||